A Phase 1 Dose Escalation Safety Study Combining the ATR Inhibitor M6620 With Chemoradiotherapy in Oesophageal Cancer & Other Solid Cancers Using Time to Event Continual Reassessment Method
| Registry | NCT03641547, acronym CHARIOT |
|---|---|
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional; na, single group, masking: none, treatment |
| Enrollment | 36 (Actual) |
| Sponsor | University of Oxford (Other); collaborators: Merck KGaA, Darmstadt, Germany |
| Conditions | Oesophageal Adenocarcinoma, Squamous Cell Carcinoma, Solid Tumor |
| Interventions | M6620, Cisplatin, Capecitabine, Radiotherapy (Drug, radiation) |
| Dates | start 2018-12-04, primary completion 2022-04-04, completion 2022-04-04, first posted 2018-08-22, last updated 2024-07-18 |
| Locations | 5 sites in United Kingdom |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Oesophageal Adenocarcinoma All trials for Squamous Cell Carcinoma All trials of M6620 All trials of Cisplatin
This Phase I study will test the combination of a novel ATR inhibitor (M6620) with chemoradiotherapy in oesophageal cancer; utilizing three experimental cohorts (Stage A1, A2 and B).
There is strong scientific rationale for combining ATR inhibitors with DNA damaging agents such as radiation and cisplatin. In particular, ATR inhibition has been shown to be cytotoxic to tumor cells with an impaired DNA damage response, such as those with deficiency in the ATM- or p53 pathway. The high incidence of p53 mutations and the fact that cisplatin and radiation are key therapeutics, makes oesophageal cancer an attractive tumor type to test the activity of an ATR inhibitor. Given the reported synthetic lethal relationship between ATM and ATR, it is likely that ATR inhibition in an ATM- or p53- deficient background will offer a specific and effective way of targeting OAC and SCC of the oesophagus, and enhance the current standard of care.
The trial will be divided into three stages. Stage A1 will explore the combination of M6620 plus radiotherapy in the palliative setting and Stage A2 will explore the combination of M6620 plus chemotherapy in the palliative setting. Stage B, will explore the combination of all 3 (M6620 plus chemoradiotherapy in the radical setting).
In Stage A1 of the study M6620 will be combined with radiotherapy for the first time and the starting dose will be 140mg/m2 M6620, which has been well-tolerated. M6620 will be administered with daily palliative radiotherapy during this stage in order to study the specific interaction of M6620 with radiotherapy (acting as the DNA damaging agent during this trial stage).
In Stage A2 of the study, M6620 will be combined with Cisplatin and Capecitabine combination chemotherapy for the first time; with a starting dose of 90mg/m2 M6620. M6620 will be administered 24 hours post cisplatin infusion, aiming to achieve maximum treatment benefit. Stage A1 and A2 together will help give an indication of a toxicity profile before administration with chemoradiotherapy (Stage B).
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Stage A1, A2 & B | Experimental | Drug: M6620; Drug: Cisplatin; Drug: Capecitabine; Radiation: Radiotherapy | The trial is a single arm study. Different populations are recruited to each stage and the stages run independently of each other. Stage A1 \& A2 will commence before Stage B so that safety data can be obtained in the palliative setting prior to Stage B commencing. Stage A1 may be ongoing when Stage B begins. Each Stage has a separate eligibility criteria. Stage A1: M6620 \& palliative radiotherapy Stage A2: M6620 \& palliative chemotherapy (Cisplatin \& Capecitabine) Stage B: M6620 \& definitive chemoradiotherapy |
Sex: All, ages: 16 Years to any
INCLUSION CRITERIA:
For Stage A1:
1. Histologically confirmed adenocarcinoma or squamous cell carcinoma of the oesophagus (not including cervical oesophagus)
2. Tumor length 15cm or less
3. Any stage of disease that is unsuitable for radical CRT or surgery but suitable for palliative RT
4. Baseline investigations available: staging CT scan (within 42 days before first study dose) and endoscopy
5. Previous chemotherapy treatment completed 28 days before first study dose
6. No oesophageal stent in-situ
7. Any gender, aged ≥16 years.
8. Life expectancy of at least 12 weeks
9. ECOG performance score of 0-1
10. Able to comply with protocol fully - absence of any physical, psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
11. Able to give written (signed and dated) informed consent according to GCP before registration
12. Hematological and biochemical indices within the ranges below:
* Haemoglobin: ≥8.0g/dL
* Platelet count : ≥100x10\^9/L
* Absolute neutrophil count: ≥1.5x10\^9/L
* Total bilirubin: ≤1.5 x upper limit of normal unless the subject has known or suspected Gilbert's syndrome
* AST/ALT: ≤2.5 times the upper limit of normal; ≤5 times if liver metastases
* Estimated glomerular filtration rate: ≥40ml/min
For Stage A2:
1. Any histologically confirmed advanced solid tumor that is metastatic or unresectable where Investigator considers Cisplatin and Capecitabine based regimen as appropriate.
2. Baseline investigations available: staging CT scan (within 35 days before first study dose)
3. Previous chemotherapy treatment completed 28 days before first study dose
4. Any gender, aged ≥16 years
5. Life expectancy of at least 12 weeks
6. ECOG performance score of 0-1
7. Able to comply with protocol fully - absence of any physical, psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
8. Able to give written (signed and dated) informed consent according to GCP before registration
9. Hematological and biochemical indices within the ranges below:
* Haemoglobin: ≥10.0g/dL
* Platelet count : ≥100x10\^9/L
* Absolute neutrophil count: ≥1.5x10\^9/L
* Total bilirubin: ≤1.5 x upper limit of normal unless the subject has known or suspected Gilbert's syndrome
* AST/ALT: ≤2.5 times the upper limit of normal; ≤5 times if liver metastases
* Ca, Mg, Phosphate: within normal limits
* Estimated glomerular filtration rate: ≥60ml/min
For Stage B:
1. Histologically confirmed adenocarcinoma or squamous cell carcinoma of the oesophagus including Siewert type 1 or 2 tumors with ≤2cm gastric mucosal extension (not including cervical oesophagus)
2. Tumor length 7cm or less
3. Suitable for radical CRT and surgery not an option due to being medically unfit or unsuitable for surgery or patient choice
4. No oesophageal stent in-situ
5. Endoscopically or radiologically documented measurable disease
6. Diagnostic PET CT scan*
7. Staging CT scan*
*either CT or PET CT scan within 42 days of first study dose
8. Adequate respiratory and cardiac function tests for safe delivery of CRT in the opinion of the Principle Investigator, specifically cardiac ejection fraction ≥60% and lung function FEV1>1 litre or 40% of predicted value or KCO (DLCO/VA) >40% predicted value.
9. Any gender, aged ≥16 years
10. ECOG performance score of 0-1
11. Able to comply with protocol fully - absence of any physical, psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
12. Able to give written (signed and dated) informed consent according to GCP before registration
13. Haematological and biochemical indices within the ranges below:
* Haemoglobin: ≥10.0g/dL
* Platelet count : ≥100x10\^9/L
* Absolute neutrophil count: ≥1.5x10\^9/L
* Total bilirubin: ≤1.5 x upper limit of normal unless the subject has known or suspected Gilbert's syndrome
* AST/ALT: ≤2.5 times the upper limit of normal; ≤5 times if liver metastases
* Ca, Mg, Phosphate: within normal limits
* Estimated glomerular filtration rate: ≥60ml/min
EXCLUSION CRITERIA:
1. Pregnant or breast-feeding women, or women of childbearing potential unless highly effective contraception is used
2. Untreated and multiple brain metastases
3. Clinically significant cardiovascular event within 6 months before study entry to include: a) congestive heart failure requiring therapy, b) unstable angina pectoris, c) myocardial infarction, d) class II/III/IV cardiac disease (New York Heart Association), e) presence of severe valvular heart disease, f) presence of ventricular arrhythmia requiring treatment
4. History of arrhythmia that is symptomatic or requires treatment (CTCAE 3), symptomatic or uncontrolled atrial fibrillation, despite treatment, or asymptomatic sustained ventricular tachycardia. Subjects with atrial fibrillation controlled by medication are permitted.
5. Uncontrolled hypertension (blood pressure ≥160/100 despite optimal therapy)
6. Second or third degree heart block with or without symptoms
7. QTc >450msec in adult male and >470 msec in adult females (by Fridericia's correction) not due to electrolyte abnormality and that does not resolve with correction of electrolytes.
8. History of congenital long QT syndrome
9. History of torsades de pointes (or any concurrent medication with a known risk of inducing torsades de pointes)
10. Trachea-oesophageal fistula or invasion of the tracheo-bronchial tree
11. Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to the start of treatment
12. Strong CYP3A inhibitors and inducers or haemopoietic growth factors within 14 days before first dose of M6620 (Berzosertib)
13. HER2 gastro-oesophageal positive cancer where anti-Her2 therapies may be more appropriate (however patients who have failed anti-HER2 therapy may be eligible for stage A1 and A2)
14. Unable to have or unwilling to change to low molecular weight heparin instead of Warfarin
15. Other psychological, social or medical condition, physical examination finding or a laboratory abnormality that the Investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results.
16. Any other active malignancy, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and non-melanoma skin lesions.
17. Patients who are known to be serologically positive for Hepatitis B, Hepatitis C or HIV.
Additional Exclusion Criteria for Stage A1 and B:
1\) Previous radiotherapy to thorax or upper abdomen
Additional exclusion criteria for Stage A2 and B:
1. History of hand-foot syndrome
2. History of hearing impairment
3. Live vaccine received within 30 days prior to treatment start
4. Complete or Partial DPD deficiency
Additional Exclusion Criteria for Stage B:
1\) Previous chemotherapy| Milestone | A1 - Dose Level 1 | A1 - Dose Level 2 | A1 - Dose Level 3 | A1 - Dose Level 4 | A1 - Dose Level 5 | A1 - Dose Level 6 | A2 - Dose Level 1 | A2 - Dose Level 2 | A2 - Dose Level 3 | A2 - Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 1 | 1 | 1 | 1 | 9 | 5 | 1 | 9 | 5 |
| Completed | 3 | 1 | 1 | 1 | 1 | 9 | 2 | 1 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 5 | 2 |
Time frame: Stage A1 - adverse events (including serious) are reported from start of M6620 (Berzosertib) treatment to follow up visit at 9 weeks post-end of treatment (12 weeks). Stage A2 - adverse events (including serious) are reported from start of M6620 (Berzosertib) treatment to follow up visit at 8 weeks post-end of treatment (26 weeks). Both Stages - Mortality is reported from start of M6620 (Berzosertib) treatment to patient completion of trial at 12 months after start of treatment (12 months).
| Arm | Deaths | Serious adverse events | Other adverse events |
|---|---|---|---|
| A1 - Dose Level 1 | 1/3 (33.3%) | 0/3 (0.0%) | 3/3 (100.0%) |
| A1 - Dose Level 2 | 1/1 (100.0%) | 0/1 (0.0%) | 1/1 (100.0%) |
| A1 - Dose Level 3 | 0/1 (0.0%) | 0/1 (0.0%) | 1/1 (100.0%) |
| A1 - Dose Level 4 | 1/1 (100.0%) | 0/1 (0.0%) | 1/1 (100.0%) |
| A1 - Dose Level 5 | 1/1 (100.0%) | 0/1 (0.0%) | 1/1 (100.0%) |
| A1 - Dose Level 6 | 5/9 (55.6%) | 2/9 (22.2%) | 9/9 (100.0%) |
| A2 - Dose Level 1 | 3/5 (60.0%) | 0/5 (0.0%) | 4/5 (80.0%) |
| A2 - Dose Level 2 | 1/1 (100.0%) | 0/1 (0.0%) | 1/1 (100.0%) |
| A2 - Dose Level 3 | 5/9 (55.6%) | 3/9 (33.3%) | 9/9 (100.0%) |
| A2 - Dose Level 4 | 2/5 (40.0%) | 0/5 (0.0%) | 4/5 (80.0%) |
| Term | Organ system | A1 - Dose Level 1 | A1 - Dose Level 2 | A1 - Dose Level 3 | A1 - Dose Level 4 | A1 - Dose Level 5 | A1 - Dose Level 6 | A2 - Dose Level 1 | A2 - Dose Level 2 | A2 - Dose Level 3 | A2 - Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gastrostomy tube site complication | Injury, poisoning and procedural complications | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 1/9 | 0/5 | 0/1 | 0/9 | 0/5 |
| Pyrexia | General disorders | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 0/9 | 0/5 | 0/1 | 1/9 | 0/5 |
| Chest pain | General disorders | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 0/9 | 0/5 | 0/1 | 1/9 | 0/5 |
| Neutropenia | Blood and lymphatic system disorders | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 0/9 | 0/5 | 0/1 | 1/9 | 0/5 |
| Constipation | Gastrointestinal disorders | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 1/9 | 0/5 | 0/1 | 0/9 | 0/5 |
| Vomiting | Gastrointestinal disorders | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 0/9 | 0/5 | 0/1 | 1/9 | 0/5 |
| Rash maculo-papular | Skin and subcutaneous tissue disorders | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 1/9 | 0/5 | 0/1 | 0/9 | 0/5 |
| Sepsis | Infections and infestations | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 0/9 | 0/5 | 0/1 | 1/9 | 0/5 |
| Term | Organ system | A1 - Dose Level 1 | A1 - Dose Level 2 | A1 - Dose Level 3 | A1 - Dose Level 4 | A1 - Dose Level 5 | A1 - Dose Level 6 | A2 - Dose Level 1 | A2 - Dose Level 2 | A2 - Dose Level 3 | A2 - Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/3 | 0/1 | 0/1 | 0/1 | 0/1 | 0/9 | 0/5 | 0/1 | 0/9 | 0/5 |
| Vascular disorders | Vascular disorders | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 1/9 | 0/5 | 0/1 | 4/9 | 0/5 |
| General disorders and administration site conditions | General disorders | 2/3 | 0/1 | 0/1 | 0/1 | 1/1 | 4/9 | 3/5 | 1/1 | 5/9 | 4/5 |
| Reproductive system and breast disorders | Reproductive system and breast disorders | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 0/9 | 1/5 | 0/1 | 0/9 | 0/5 |
| Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | 1/3 | 1/1 | 1/1 | 1/1 | 1/1 | 3/9 | 2/5 | 1/1 | 2/9 | 3/5 |
| Psychiatric disorders | Psychiatric disorders | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 1/9 | 0/5 | 0/1 | 0/9 | 0/5 |
| Investigations | Investigations | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 4/9 | 1/5 | 1/1 | 5/9 | 1/5 |
| Injury, poisoning and procedural complications | Injury, poisoning and procedural complications | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 2/9 | 0/5 | 1/1 | 0/9 | 0/5 |
| Nervous system disorders | Nervous system disorders | 1/3 | 0/1 | 0/1 | 0/1 | 0/1 | 3/9 | 1/5 | 0/1 | 1/9 | 3/5 |
| Blood and lymphatic system disorders | Blood and lymphatic system disorders | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 3/9 | 2/5 | 1/1 | 6/9 | 3/5 |
| Ear and labyrinth disorders | Ear and labyrinth disorders | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 0/9 | 0/5 | 0/1 | 1/9 | 3/5 |
| Eye disorders | Eye disorders | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 1/9 | 0/5 | 1/1 | 0/9 | 1/5 |
| Gastrointestinal disorders | Gastrointestinal disorders | 2/3 | 1/1 | 1/1 | 0/1 | 1/1 | 8/9 | 2/5 | 0/1 | 6/9 | 4/5 |
| Hepatobiliary disorders | Hepatobiliary disorders | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 0/9 | 1/5 | 0/1 | 0/9 | 0/5 |
| Skin and subcutaneous tissue disorders | Skin and subcutaneous tissue disorders | 0/3 | 0/1 | 1/1 | 0/1 | 0/1 | 5/9 | 0/5 | 1/1 | 1/9 | 2/5 |
| Renal and urinary disorders | Renal and urinary disorders | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 0/9 | 1/5 | 0/1 | 0/9 | 1/5 |
| Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | 0/3 | 0/1 | 0/1 | 1/1 | 0/1 | 2/9 | 0/5 | 1/1 | 3/9 | 3/5 |
| Infections and infestations | Infections and infestations | 1/3 | 0/1 | 1/1 | 0/1 | 0/1 | 1/9 | 3/5 | 1/1 | 4/9 | 2/5 |
| Metabolism and nutrition disorders | Metabolism and nutrition disorders | 0/3 | 0/1 | 0/1 | 0/1 | 0/1 | 5/9 | 1/5 | 1/1 | 5/9 | 3/5 |
| Facility | City | Country | Status |
|---|---|---|---|
| Velindre Cancer Centre | Cardiff | United Kingdom | |
| Beatson Cancer Centre | Glasgow | United Kingdom | |
| St James's University Hospital | Leeds | United Kingdom | |
| The Christie | Manchester | United Kingdom | |
| The Churchill Hospital, Oxford University Hospitals Trust | Oxford | United Kingdom |